Background: Multiple factors can influence outcomes of patients receiving identical interventions in clinical trials and in routine practice. Here, we compare outcomes of men with metastatic castrate-resistant prostate cancer (mCRPC) treated with docetaxel and prednisone in routine practice and in clinical trials.
introduction
Data from clinical trials, although providing critical evidence of clinical activity, do not provide adequate information to judge the impact of a new treatments when used in the realworld setting [1] . The difference between results of clinical trials and outcomes in clinical practice may be explained by restrictive selection criteria for trials such as good prognosis and minimal comorbidities [2] . This is likely to be particularly important when older patients receive potentially toxic therapy, such as men with metastatic castration-resistant prostate cancer (mCRPC), since most will have pre-existing medical conditions.
Despite an increasing role for secondary and tertiary hormonal-based therapies in men with mCRPC, standard initial treatment since 2004 remains chemotherapy with docetaxel and prednisone. This is based on the international TAX-327 study, which compared docetaxel in two schedules (3-weekly and weekly) with mitoxantrone (all with prednisone) [3] . The extent to which results from the pivotal trial translate to less selected patients treated in routine practice is unknown. Here we reviewed all men treated with docetaxel for mCRPC at our institution. We hypothesized that those treated outside of a clinical trial would have poorer survival and more toxicity than those recruited to clinical trials.
patients and methods

study population
All men who received at least one dose of docetaxel for mCRPC before January 2012 at Princess Margaret Cancer Centre (PMCC) in Toronto, Canada were identified through pharmacy records. Patients treated with weekly docetaxel were excluded as this was given to men who were frail or had a high risk of toxicity. Men who received docetaxel in the context of neoadjuvant or adjuvant trials, or as second-line chemotherapy for mCRPC were also excluded. Enrollment logs of prostate cancer trials were screened to identify patients treated with docetaxel in clinical trials. The institutional Research Ethics Board (REB) approved the study.
data collection
Dates of treatment and doses were obtained from the PMCC pharmacy. Clinical data were extracted manually from the electronic patient record (EPR) by MA, PdG, and AT. Laboratory values were obtained electronically from EPR; baseline was defined as within 28 days before the first dose of docetaxel. Dates of primary diagnosis and death were obtained from the PMCC Registry, which includes 99% of patients treated in our institution. Data from all sources were linked using the patients' Medical Record Number.
outcomes of interest
The primary objective was to compare overall survival (OS) and PSA response rates in men with mCRPC treated with 3-weekly docetaxel in routine practice at PMCC with those receiving the same schedule at our institution in clinical trials evaluating docetaxel/prednisone alone (e.g. TAX-327 [3] ) or with GTI-2040 [4] , GVAX [5] , aflibercept [6] , or OGX-011 [7, 8] (supplementary Table S1 , available at Annals of Oncology online). We also compared these data with those for 332 men who received 3-weekly docetaxel in multiple institutions in the TAX-327 trial [3, 9, 10] . Secondary objectives were to compare reasons for treatment discontinuation, rates of febrile neutropenia (as described in the clinical notes), and death within 30 days of last administration of docetaxel.
statistical analysis
Descriptive statistics for categorical variables were reported as percentages, and continuous variables were reported as medians and ranges. Categorical variables were compared using Fisher's exact test and Kruskal-Wallis test for two and more variables, respectively. Continuous variables were compared by the Wilcoxon rank sum test. Dose intensity was calculated as the cumulative dose of docetaxel per body surface area divided by the time between first dose and end of the last cycle (and was 100% for 25 mg/m 2 / week). If there was >12 weeks between two administrations of docetaxel, the patient was regarded as having two separate courses and only doses in the first course were included in calculation of dose intensity.
Survival was calculated from the date of first docetaxel administration to death with censoring at date of last contact for patients alive at the cut-off date in August 2012. The Kaplan-Meier method was used to estimate survival, and survival curves were compared using the generalized Wilcoxon test; this test was preferred to log-rank since it places greater emphasis on the first part of the survival curves where the effect of treatment is more pronounced. The log-rank test was evaluated as a supportive analysis.
Association of individual variables with survival was assessed using the Cox proportional hazard model. All variables with a P-value <0.1 in univariable analysis, variables with a P-value ≥0.1 but which changed the outcome of the variable 'in trial' by more than 10%, or variables where there was a significant interaction with the variable "in trial" (P < 0.05) were retained in the multivariable model. Variables included treatment in a clinical trial, age at start of treatment, time from diagnosis until start of docetaxel, Eastern Cooperative Oncology Group performance status (ECOG PS), year of first administration, presence of visceral metastases, Gleason score (<8 versus 8-10); serum levels of prostate-specific antigen (PSA), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), hemoglobin (Hgb), and albumin. Laboratory values were treated as continuous variables. Variables with non-normal distribution (e.g. PSA, LDH, and ALP) were log transformed.
PSA response was defined as ≥50% decline of PSA compared with baseline maintained for at least 3 weeks. Men with a rise in PSA within the first 12 weeks of treatment were considered as PSA responders if subsequent values of PSA satisfied the above criterion, as per Prostate Cancer Working group 2 (PCWG2) criteria [11] .
All statistical tests were two sided, and statistical significance was defined as P < 0.05. Analyses were carried out using SAS version v9.2 (SAS Institute, Inc.) and SPSS version 20 (IBM Corp.); curves were plotted with R version 2.13.1 (www.r-project.org). Corrections for multiple significance testing were not applied. Patients' and tumor characteristics are presented in Table 1 . Men receiving treatment in routine practice were older (median age 71 versus 68 years, P = 0.038) and more likely to have an ECOG performance status of 2 or higher (29% versus 3%, P < 0.001), when compared with those treated in a clinical trial.
treatment received
Comparisons of outcomes of patients treated on trial and offtrial, as well as those in the TAX-327 study, are presented in Table 2 . Trial patients received more cycles of docetaxel (median: 8 versus 6, P = 0.001) whereas overall dose-intensity, dose reductions and delays by cycle 6 were similar. The median number of cycles and delayed infusions in TAX-327 were similar to those in PMCC patients whereas dose reductions occurred less often (P < 0.001).
overall survival and PSA response Median OS for all nontrial patients receiving 3-weekly docetaxel with prednisone was 13.6 months, compared with 20.4 months for PMCC trial patients (P = 0.007) and 19.3 months in TAX-327 (P < 0.001; Figure 2 ). One-year and 2-year OS rates were higher for patients treated in clinical trials (Table 3 ). There was no significant difference in survival between trial patients in our institution and men treated on the TAX-327 study (with or without exclusion of the 7 PMCC patients who participated in TAX-327). In an exploratory analysis patients who would have met the selection criteria for the TAX-327 trial lived significantly longer compared with those not meeting the selection criteria (median survival 16.7 versus 9.0 months, Compared with nontrial patients, patients receiving docetaxel in a clinical trial at PMCC had a reduced hazard of death in univariable analysis (HR = 0.74, Wilcoxon P = 0.007, Figure 2 ) but 'trial treatment' was not an independent prognostic factor in multivariable analysis (Table 4) . Factors associated with longer survival were higher hemoglobin, lower LDH at baseline, longer time from initial diagnosis, and more recent treatment.
There was no significant difference in PSA response rates between patients treated in daily practice, in a clinical trial at PMCC, or on the TAX-327 study (Table 3) . toxicity Overall, the rates for treatment discontinuation because of toxicity were the same, even when comparing discontinuation rates for toxicity by cycle 6 ( Table 2) . Febrile neutropenia occurred in 9.6% of nontrial patients (in 60% of the cases during cycle 1); in none of the PMCC trial patients (P = 0.035) and in 3% of men in TAX-327 (P < 0.001). Deaths within 30 days of the last administration of docetaxel occurred in 4% of men treated in routine practice whereas no such events were observed in PMCC trial patients (P = 0.24), and 3% in the TAX-327 study (P = 0.68).
discussion
The purpose of the present study was to compare outcomes of men with mCRPC treated with docetaxel and prednisone in routine practice and in clinical trials. We therefore reviewed all patients treated with first-line 3-weekly docetaxel for mCRPC at our institution and compared outcomes of men treated in routine clinical practice with those in clinical trials, both within our institution and in the pivotal TAX-327 study. The results support our hypothesis that men treated in routine practice have shorter survival and more toxicity than men treated within clinical trials.
The difference in median survival between men treated in routine practice and in trials at PMCC (13.6 versus 20.4 months) was larger than reported in other series [12] [13] [14] . The difference between outcomes in clinical trials and clinical practice is known as the efficacy-effectiveness gap [1, 15, 16] . The outcome of men treated in clinical trials at our institution was similar to those treated in the TAX-327 study (median OS 19.3 months [9] ), and we explored a potential 'trial effect' by performing multivariable analyses to assess whether treatment in a clinical trial was an independent prognostic factor. This might be expected because of strict rules for assessment or management of toxicity [13] . No such association was observed in multivariable analysis, suggesting that selection of patients with favorable prognosis accounts for the observed difference in OS between trial and nontrial patients. Patients treated in clinical trials were younger, had less comorbidity and better performance status. These findings are consistent with a meta-analysis that did not find evidence that enrollment in clinical trials is an independent prognostic factor [17] .
Patients treated in routine practice in our institution had more toxicity than those treated in clinical trials: they received less cycles of docetaxel, but had a 9.6% rate of febrile neutropenia compared with 0 and 3% for PMCC trial patients and participants of the TAX-327 study, respectively. However, the rate of all-cause death within 30 days was not significantly different (4% in routine practice, 0% in trial patients, and 3% in TAX-327). The high rate of febrile neutropenia cautions the use of toxic treatment in men with mCRPC who would not have met criteria for trial selection. Registration trials use strict selection criteria to show maximum efficacy and minimal toxicity but most new therapies add toxicity [18] , and these toxicities may only become apparent when treatment is applied in routine practice [19] . Ideally, registration trials should be 
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Inherent limitations of this study are its retrospective nature and manual extraction of clinical data. This may have led to under-detection of comorbidities since they were not systematically reported in clinical notes, inaccurate assessment of performance status (often not mentioned explicitly), and nonavailability of relevant data (e.g. Gleason scores). For some men, no single reason for treatment discontinuation could be identified, making assignment to a specific group difficult or arbitrary. Rates of febrile neutropenia were based on clinical notes, which did not always provide the degree of fever or the absolute neutrophil count and may have led to an overestimation. In contrast, some patients might have been admitted to peripheral hospitals with underdetection of febrile neutropenia. We evaluated year of first administration of docetaxel to account for possible earlier use of chemotherapy in more recent years, and increasing use of further treatments given after it (although only six patients included in this analysis received abiraterone acetate). Other limitations are that patients treated at a referral center are likely to represent a selected cohort, and our inability to adjust for unmeasured confounders.
In conclusion, our results support the hypothesis that application of results from clinical trials establishing the efficacy of a new cancer treatment leads to poorer outcomes and greater toxicity when applied in routine practice. Specifically, routine treatment of men with mCRPC with docetaxel is associated with a higher rate of febrile neutropenia and shorter survival than for men who are recruited to clinical trials. These findings are probably due to less rigorous patient selection for treatment in routine practice.
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